Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 16Colorectal Neoplasms 4Brain Neoplasms 4Neoplasms 3Meningeal Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Rectal Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Colonic Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Pathologic Complete Response 1Metastatic Breast Cancer With a Isolated Brain Progression 1Meningeal Carcinomatosis 1Hemangiosarcoma 1HER2-positive Gastric Cancer 1HER2-positive Breast Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Cisplatin 67Paclitaxel 32Radiotherapy 31Carboplatin 23Bevacizumab 21pembrolizumab 20Brachytherapy 18atezolizumab 11Nivolumab 10Gemcitabine 10camrelizumab 9tislelizumab 8Topotecan 8Taxes 8Drug Therapy 8Radiation 7Docetaxel 7Chemoradiotherapy 7zimberelimab 6toripalimab 6nimotuzumab 6Magnetic Resonance Spectroscopy 6Cetuximab 6Albumin-Bound Paclitaxel 6lenvatinib 5durvalumab 5dostarlimab 5Platinum 5Papillomavirus Vaccines 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uterine Cervical Neoplasms × tucatinib × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡